CN Patent

CN105859691A — 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法

Assigned to NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd · Expires 2016-08-17 · 10y expired

What this patent protects

本发明具体公开了5‑氯‑6‑（1‑（2‑亚氨基吡咯烷基）甲基）尿嘧啶盐酸盐的一种新型结晶形式，并公开了该晶型的制备方法；该晶型具有易于制备、溶解性高等优点，能够作为胸苷磷酸化酶抑制剂用于制备治疗结直肠癌的药物。

USPTO Abstract

本发明具体公开了5‑氯‑6‑（1‑（2‑亚氨基吡咯烷基）甲基）尿嘧啶盐酸盐的一种新型结晶形式，并公开了该晶型的制备方法；该晶型具有易于制备、溶解性高等优点，能够作为胸苷磷酸化酶抑制剂用于制备治疗结直肠癌的药物。

Drugs covered by this patent

Patent Metadata

Patent number: CN105859691A
Jurisdiction: CN
Classification: —
Expires: 2016-08-17
Drug substance claim: No
Drug product claim: No
Assignee: NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.